RYE, N.Y., Nov. 10 /PRNewswire/ -- Curemark, LLC, a drug research and development company currently developing a treatment for autism, was one of 32 biotech companies headed by women selected to present at the Springboard Enterprises AllThingsLifeSciences 2009 forum, held recently in Silicon Valley, Madison, Wisconsin, and New York City. More than 100 companies from the U.S. and abroad applied to participate.
"The opportunity to present our science, discuss our progress and share ideas with the investors and biotech CEOs attending the Springboard Forum was an invaluable experience for us," said Dr. Joan Fallon, founder and CEO of Curemark. "We applaud the vision of Springboard founder Kay Koplovitz in conceiving these Forums as a way to support the growth of entrepreneurial ventures headed by women and help facilitate their ability to secure financing."
Curemark now is enrolling patients at 12 sites across the country in Phase III clinical trials for CM-AT, one of the first therapies targeted to address the underlying physiology of autism. CM-AT is based on research by Dr. Fallon that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. The company announced in August that it had closed a $6.5 million Series A financing round.
Founded in 1999, Springboard Enterprises is a non-profit organization that facilitates access to the equity markets for women entrepreneurs. Springboard recruits, educates, showcases and supports high growth businesses led by women as they seek venture capital. At Springboard Forums, women entrepreneurs and CEOs pitch their emerging growth ventures to private equity investors, effectively fast-tracking the pipeline for venture capital financing. The 400 companies that have been selected to present at Springboard forums have raised over $4.5 billion in equity, grants and strategic investments.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark, LLC